MiMedx Group (NASDAQ:MDXG) Releases Earnings Results, Meets Expectations

MiMedx Group (NASDAQ:MDXG) issued its earnings results on Wednesday. The company reported $0.07 EPS for the quarter, meeting analysts’ consensus estimates of $0.07, Zacks reports. The business had revenue of $92.91 million during the quarter, compared to analysts’ expectations of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%.

MiMedx Group Stock Up 4.0 %

MiMedx Group stock traded up $0.32 during mid-day trading on Thursday, reaching $8.33. 279,895 shares of the company’s stock were exchanged, compared to its average volume of 555,213. The company has a market cap of $1.22 billion, a P/E ratio of 15.01 and a beta of 1.94. MiMedx Group has a twelve month low of $5.47 and a twelve month high of $10.14. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The company has a fifty day moving average of $8.75 and a 200-day moving average of $7.68.

Wall Street Analyst Weigh In

Several research firms have weighed in on MDXG. StockNews.com lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of MiMedx Group in a report on Thursday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, MiMedx Group currently has a consensus rating of “Buy” and a consensus price target of $12.40.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.